Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Carcinoma
100%
Malignant Neoplasm
77%
Epidermal Growth Factor Receptor
72%
Neoplasm
57%
Clinical Trial
47%
Epidermal Growth Factor Receptor Kinase Inhibitor
46%
Diseases
39%
Monoclonal Antibody
38%
Circulating Tumor DNA
38%
Minimal Residual Disease
30%
Cetuximab
26%
Chemotherapy
25%
Non Small Cell Lung Cancer
24%
Solid Malignant Neoplasm
23%
Metastatic Colorectal Cancer
23%
Vasculotropin
22%
Vandetanib
16%
Overall Survival
15%
Bortezomib
15%
Angiogenesis Inhibitor
15%
Glycan
15%
Immunotherapy
15%
Phase II Trials
15%
Leukocyte Antigen
15%
Lung Cancer
14%
Erlotinib
13%
Antitumor Activity
13%
Vasculotropin Receptor
13%
Pancreas Cancer
11%
Disease Free Survival
11%
Cancer Model
11%
Colon Carcinoma
11%
Tumor Growth
11%
Cytotoxic Agent
10%
Recurrent Disease
10%
Gefitinib
9%
Proteasome
9%
Bevacizumab
9%
Phase I Trials
9%
Biological Marker
8%
Selumetinib
7%
Receptor
7%
Sorafenib
7%
Small Interfering RNA
7%
Cyclophosphamide
7%
Vasculotropin Receptor 1
7%
Volume of Distribution
7%
Colorectal Tumor
7%
Cediranib
7%
Ovary Cancer
7%
Medicine and Dentistry
Colorectal Carcinoma
71%
Neoplasm
36%
Epidermal Growth Factor Receptor
33%
Clinical Trial
32%
Circulating Tumor DNA
28%
Diseases
24%
Human Leukocyte Antigen
24%
Malignant Neoplasm
23%
Minimal Residual Disease
22%
Vasculotropin
22%
Heterozygosity
21%
Monoclonal Antibody
19%
Overall Survival
19%
Tumor Cell
18%
Biological Marker
18%
Cancer Therapy
17%
Immunotherapy
17%
Microsatellite Instability
16%
Angiogenesis Inhibitor
15%
Immune Checkpoint Blockade
15%
Cancer Cell Line
15%
Anti-Epidermal Growth Factor Receptor
15%
Metastatic Colorectal Cancer
15%
Pancreas Cancer
13%
Epidermal Growth Factor Receptor Kinase Inhibitor
12%
Cancer Model
11%
Antineoplastic Activity
11%
Vasculotropin Receptor
11%
Cancer Treatment
10%
Recurrent Disease
10%
Disease Free Survival
9%
Bevacizumab
9%
Immune Checkpoint Inhibitor
9%
Cancer Cell
9%
Solid Malignant Neoplasm
8%
Immunity
8%
Adjuvant Therapy
8%
Personalized Medicine
8%
Signal Transduction Inhibitor
7%
Vasculotropin Receptor 1
7%
Selumetinib
7%
Antiangiogenic
7%
Angiogenesis
7%
Xenograft
7%
Cytotoxicity
7%
Ticilimumab
7%
Immune-Related Adverse Events
7%
Cediranib
7%
Carcinoembryonic Antigen Related Cell Adhesion Molecule 1
7%
Histone Deacetylase
7%
Keyphrases
Epidermal Growth Factor Receptor Inhibitors
40%
Epidermal Growth Factor Receptor
37%
Colorectal Cancer
33%
Circulating Tumor DNA (ctDNA)
30%
Anti-EGFR
25%
Metastatic Colorectal Cancer (mCRC)
23%
Immune Checkpoint Blockade
22%
Minimal Residual Disease
22%
Cancer Cells
20%
Monoclonal Antibody
19%
Vascular Endothelial Growth Factor
18%
Vascular Endothelial Growth Factor Receptor (VEGFR)
18%
Cetuximab
18%
Antitumor Activity
17%
Non-small Cell Lung Cancer (NSCLC)
17%
Disease Control
16%
Overall Survival
15%
Microsatellite Stable Colorectal Cancer
15%
Antiproliferative Activity
15%
Treatment Termination
15%
Targeted Agents
15%
NEO-201
15%
Erlotinib
15%
Cancer Cell Lines
14%
Microsatellite Instability-high (MSI-H)
13%
Colorectal Cancer Patients
13%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
12%
Cancer Treatment
11%
Immune Checkpoint Inhibitors
10%
Clinical Trials
10%
Receptor Blocking
10%
Cytotoxic Drugs
10%
Small Molecules
10%
Tumor
9%
Disease-free Survival
9%
Single Center
9%
Patients with Colorectal Cancer
9%
Gefitinib
9%
Acquired Resistance
9%
Retrospective Analysis
9%
Growth Factor Pathway
8%
ZD6474
8%
Autocrine Signaling
8%
Confidence Interval
8%
DNA Testing
8%
Adjuvant Therapy
8%
Colorectal Cancer Cells
8%
Combined Therapy
7%
Stereotactic Body Radiation Therapy
7%
AZD2171
7%